Addressing Heterogeneity in Direct Analysis of Extracellular Vesicles and Their Analogs by Membrane Sensing Peptides as Pan‐Vesicular Affinity Probes

• Published in: Advanced science 2024-08, Vol.11 (29), p.e2400533-n/a
• Main Authors: Gori, Alessandro, Frigerio, Roberto, Gagni, Paola, Burrello, Jacopo, Panella, Stefano, Raimondi, Andrea, Bergamaschi, Greta, Lodigiani, Giulia, Romano, Miriam, Zendrini, Andrea, Radeghieri, Annalisa, Barile, Lucio, Cretich, Marina
• Format: Article
• Language: English
• Subjects: Biomarkers; Biomarkers - metabolism; Blood; Body fluids; cardiovascular disease; digital detection; exosomes; Extracellular vesicles; Extracellular Vesicles - metabolism; Humans; isolation; Lipids; Peptides; Peptides - metabolism; Plasma; Proteins; single molecule array
• ISSN: 2198-3844; 2198-3844
• DOI: 10.1002/advs.202400533

Extracellular vesicles (EVs), crucial mediators of cell‐to‐cell communication, hold significant diagnostic potential due to their ability to concentrate protein biomarkers in bodily fluids. However, challenges in isolating EVs from biological specimens hinder their widespread use. The preferred strategy involves direct analysis, integrating isolation and analysis solutions, with immunoaffinity methods currently dominating. Yet, the heterogeneous nature of EVs poses challenges, as proposed markers may not be as universally present as thought, raising concerns about biomarker screening reliability. This issue extends to EV‐mimics, where conventional methods may lack applicability. Addressing these challenges, the study reports on Membrane Sensing Peptides (MSP) as pan‐vesicular affinity ligands for both EVs and their non‐canonical analogs, streamlining capture and phenotyping through Single Molecule Array (SiMoA). MSP ligands enable direct analysis of circulating EVs, eliminating the need for prior isolation. Demonstrating clinical translation, MSP technology detects an EV‐associated epitope signature in serum and plasma, distinguishing myocardial infarction from stable angina. Additionally, MSP allow analysis of tetraspanin‐lacking Red Blood Cell‐derived EVs, overcoming limitations associated with antibody‐based methods. Overall, the work underlines the value of MSP as complementary tools to antibodies, advancing EV analysis for clinical diagnostics and beyond, and marking the first‐ever peptide‐based application in SiMoA technology. Membrane Sensing Peptides (MSP) serve as pan‐vesicular affinity ligands in a “one bead – multiple markers” approach, enabling direct EV analysis in serum and plasma. MSP technology is showcased in distinguishing myocardial infarction from stable angina and allows analysis of tetraspanin‐lacking vesicles such as Red Blood Cell‐derived EVs. MSP enhances EV analysis, marking the first peptide‐based application in SiMoA technology.